(4S)-6-iodochroman-4-amine | 676133-69-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并吡喃
• 英文名称: (4S)-6-iodochroman-4-amine
• 英文别名: (4S)-6-iodo-3,4-dihydro-2H-chromen-4-amine
• CAS: 676133-69-0
• 化学式: C₉H₁₀INO
• 分子量: 275.089
• InChiKey: IMWOQKPUSMKPEC-QMMMGPOBSA-N

物化性质

• 沸点：
  305.9±42.0 °C(Predicted)
• 密度：
  1.752±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.6
• 重原子数：
  12
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  35.2
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  (4S)-6-iodochroman-4-amine 在 二氯双(三邻甲苯膦)合钯(II) 、 二乙胺基三氟化硫 、 三正丁基甲氧基锡 、 三乙胺 作用下， 以 四氢呋喃 、 二氯甲烷 、 甲苯 为溶剂， 生成 tert-butyl N-[(4S)-6-(2-fluoro-2-methylpropyl)-3,4-dihydro-2H-chromen-4-yl]carbamate
  参考文献：
  名称：

  Design and synthesis of hydroxyethylamine (HEA) BACE-1 inhibitors: Prime side chromane-containing inhibitors

  摘要：

  The structure structure activity relationship of the prime region of conformationally restricted hydroxyethylamine (HEA) BACE inhibitors is described. Variation of the P1' region provided selectivity over Cat-D with a series of 2,2-dioxo-isothiochromanes and optimization of the P2' substituent of chromane-HEA(s) with polar substituents provided improvements in the compound's in vitro permeability. Significant potency gains were observed with small aliphatic substituents such as methyl, n-propyl, and cyclopropyl when placed at the C-2 position of the chromane. (C) 2013 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2013.06.006
• 作为产物：
  描述：

  (R)-6-iodochroman-4-ol 在 lithium aluminium tetrahydride 、 叠氮磷酸二苯酯 、 1,8-二氮杂双环[5.4.0]十一碳-7-烯 作用下， 以 乙醚 为溶剂， 生成 (4S)-6-iodochroman-4-amine
  参考文献：
  名称：

  Design and synthesis of hydroxyethylamine (HEA) BACE-1 inhibitors: Prime side chromane-containing inhibitors

  摘要：

  The structure structure activity relationship of the prime region of conformationally restricted hydroxyethylamine (HEA) BACE inhibitors is described. Variation of the P1' region provided selectivity over Cat-D with a series of 2,2-dioxo-isothiochromanes and optimization of the P2' substituent of chromane-HEA(s) with polar substituents provided improvements in the compound's in vitro permeability. Significant potency gains were observed with small aliphatic substituents such as methyl, n-propyl, and cyclopropyl when placed at the C-2 position of the chromane. (C) 2013 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2013.06.006

文献信息

• Amino-oxetanes as amide isosteres by an alternative defluorosulfonylative coupling of sulfonyl fluorides
  作者：Juan J. Rojas、Rosemary A. Croft、Alistair J. Sterling、Edward L. Briggs、Daniele Antermite、Daniel C. Schmitt、Luka Blagojevic、Peter Haycock、Andrew J. P. White、Fernanda Duarte、Chulho Choi、James J. Mousseau、James A. Bull

  DOI：10.1038/s41557-021-00856-2

  日期：2022.2

  This disconnection, comparable to a typical amidation, will allow the application of vast existing amine libraries. The reaction is tolerant to a wide range of polar functionalities and is suitable for array formats. Ten oxetane analogues of bioactive benzamides and marketed drugs are prepared. Kinetic and computational studies support the formation of an oxetane carbocation as the rate-determining

  生物等排体提供了有价值的设计元素，药物化学家可以使用这些元素将生物活性化合物的结构和药代动力学特征调整为可行的候选药物。芳基氧杂环丁胺作为苯甲酰胺（非常常见的药效团）的生物等排体具有令人兴奋的潜力，但由于缺乏可用的合成方法而很少被检查。在这里，我们描述了磺酰氟通过已建立的 SuFEx（磺酰氟交换）点击反应性的替代途径形成氨基氧杂环丁烷的一类反应。脱氟磺酰化仅在加热时形成平面氧杂环丁烷碳正离子。这种断开与典型的酰胺化相当，将允许应用大量现有的胺库。该反应对多种极性官能团具有耐受性，适用于阵列形式。制备了十种具有生物活性的苯甲酰胺和已上市药物的氧杂环丁烷类似物。动力学和计算研究支持氧杂环丁烷碳正离子的形成作为速率决定步骤，然后是化学选择性亲核偶联步骤。
• Methods of treatment of amyloidosis using bi-cyclic aspartyl protease inhibitors
  申请人：John Varghese

  公开号：US20050239832A1

  公开（公告）日：2005-10-27

  The invention relates to novel compounds and methods of treating diseases, disorders, and conditions associated with amyloidosis. Amyloidosis refers to a collection of diseases, disorders, and conditions associated with abnormal deposition of A-beta protein.

  本发明涉及新型化合物和治疗与淀粉样变性相关的疾病、紊乱和状况的方法。淀粉样变性是指与A-beta蛋白异常沉积相关的一系列疾病、紊乱和状况的集合。
• 2-Amino- and 2-thio- substituted 1,3-diaminopropanes
  申请人：Hom Roy

  公开号：US20050267199A1

  公开（公告）日：2005-12-01

  Disclosed are compounds of the formula: where variables Q, Z, X, R 15 , R 2 , R 3 , and R c are defined herein. Compounds disclosed herein are inhibitors of the beta-secretase enzyme and are therefore useful in the treatment of Alzheimer's disease and other diseases characterized by deposition of A beta peptide in a mammal.

  本发明揭示了以下式子的化合物：其中变量Q、Z、X、R15、R2、R3和R4在此定义。本发明揭示的化合物是β-分泌酶酶的抑制剂，因此在治疗老年痴呆症和其他以哺乳动物体内A beta 肽沉积为特征的疾病中有用。
• Acetyl 2-hydroxy-1, 3-diaminoalkanes
  申请人：——

  公开号：US20040180939A1

  公开（公告）日：2004-09-16

  Disclosed are compounds of the formula: 1 where variables Z, X, R 15 , R 2 , R 3 , and R c are defined herein. Compounds disclosed herein are inhibitors of the beta-secretase enzyme and are therefore useful in the treatment of Alzheimer's disease and other diseases characterized by deposition of A beta peptide in a mammal.

  本发明揭示了公式1的化合物：其中变量Z、X、R15、R2、R3和Rc的定义如下。本发明所揭示的化合物是β-分泌酶酶的抑制剂，因此在治疗老年痴呆症和其他以A beta肽在哺乳动物中沉积为特征的疾病方面有用。
• 2-amino- and 2-thio- substituted 1,3-diaminopropanes
  申请人：Elan Pharmaceuticals, Inc.

  公开号：US07544717B2

  公开（公告）日：2009-06-09

  Disclosed are compounds of the formula: where variables Q, Z, X, R15, R2, R3, and Rc are defined herein. Compounds disclosed herein are inhibitors of the beta-secretase enzyme and are therefore useful in the treatment of Alzheimer's disease and other diseases characterized by deposition of A beta peptide in a mammal.

  本发明涉及公式如下的化合物：其中变量Q、Z、X、R15、R2、R3和Rc在此定义。本发明中所披露的化合物是β-分泌酶酶的抑制剂，因此在治疗阿尔茨海默病和其他以哺乳动物中A beta肽沉积为特征的疾病中有用。